Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

BMC Cancer201515:949

https://doi.org/10.1186/s12885-015-1978-2

Received: 18 July 2015

Accepted: 5 December 2015

Published: 16 December 2015

Abstract

Background

To compare the efficacy and toxicity of irinotecan-based chemotherapy (IBC) and non-irinotecan-based chemotherapy (NIBC) as first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC).

Methods

PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), abstracts from the annual meetings of ASCO and the ESMO up to 2014 were searched for randomized controlled trials (RCTs) that compared IBC with NIBC. Data on overall survival (OS) and progression-free survival (PFS) were meta-analyzed to provide hazard ratios (HRs), while data on overall response rate (ORR) and frequencies of toxicity were meta-analyzed to provide relative risk ratios (RR).

Results

Seven RCTs (6 RCTs from Asian population and 1 from non-Asian population) involving 1473 patients with previously untreated stage IIIB/IV NSCLC were included in the meta-analysis. IBC and NIBC were associated with similar ORR (RR: 1.08, 95 %CI: 0.94 to 1.23, p = 0.30), OS (HR: 0.97, 95 %CI: 0.88 to 1.07, p = 0.56), and PFS (HR: 1.02, 95 %CI: 0.97 to 1.08, p = 0.38). However, the subgroups between Asian and non-Asian patients differed significantly in OS (HR: 0.94 vs 1.87, p = 0.007). There was no significant difference for hematological toxicity (RR: 0.79, 95 %CI: 0.60 to 1.04, p = 0.09) and significant worse for non-hematological toxicity (RR: 2.28, 95 %CI: 1.60 to3.24, p < 0.001), when IBC compared to NIBC.

Conclusions

As the available evidence suggests that IBC and NIBC are equivalent in terms of ORR, PFS, OS, at least in Asian patients, we recommend that IBC be considered as a first-line treatment in Asian patients with stage IIIB/IV NSCLC. However, the non-hematological toxicity of IBC must be considered.

Keywords

Irinotecan Chemotherapy Non-small cell lung cancer Meta-analysis

Background

Lung cancer is the leading cause of cancer-related deaths worldwide, and approximately 80 % of patients with lung cancer are non-small cell lung cancer (NSCLC). Two-thirds of patients with NSCLC are diagnosed when they are already in stage IIIB or IV [13]. Traditionally, chemotherapy is the first choice for the treatment of this status. Currently, however, the mutation status of the epidermal growth factor receptor (EGFR) and the arrangement status of anaplastic lymph kinase (ALK) are independent pathologic types in NSCLC. EGFR tyrosine kinase inhibitors (EGFR-TKIs) and ALK inhibitors show promise for treating these types and are recommended as the first choice by National Comprehensive Cancer Network (NCCN). However, the rate of EGFR positive mutation is about 20 % and ALK arrangement rate is only about 5-7 % [4]. Therefore chemotherapy is still recommended as the 1st-line treatment for stage IV NSCLC patients without EGFR mutation, ALK fusion gene arrangement or unknown for these gene mutation statuses in the NCCN guideline. Guidelines of NCCN recommend first-line treatment with platinum-doublet chemotherapy, which include paclitaxel, docetaxel, gemcitabine, etoposide, vinblastine, vinorebine, pemetrexed, and albumin-bound paclitaxel [5].

Chemotherapy based on the topoisomerase I inhibitor irinotecan may provide another option for first-line treatment of advanced NSCLC. Irinotecan-based chemotherapy (IBC) has already been shown to be effective against colorectal cancer (CRC), lung cancer, gastric cancer and gynecologic neoplasms [69]. NCCN guidelines recommend IBC as first-line treatment of metastatic CRC and extensive-stage small-cell lung cancer (SCLC). Several studies, primarily in Asian patients, suggest that IBC and non-irinotecan-based chemotherapy (NIBC) lead to similar clinical benefit and different toxicity profiles when used to treat stage IIIB or IV NSCLC. However, NCCN guidelines do not currently recommend IBC as first-line therapy for NSCLC.

Therefore we performed a systematic review and meta-analysis of randomized controlled trials comparing IBC and NIBC in patients with stage IIIB or IV NSCLC. The goal was to assess the current evidence on the efficacy and safety of IBC in a relatively large cohort in order to help clinicians identify whether IBC is appropriate as first-line chemotherapy regimen.

Methods

Search strategy

We searched PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) up to April 2014 without any limitations on publication year or language. The search terms “non-small cell lung cancer”, “NSCLC”, “irinotecan”, and “CPT-11”were used. Abstracts published at the annual meetings of the American Society of Clinical Oncology and the European Society for Medical Oncology from 2000 onwards was also searched. Reference lists in original articles and review articles were manually searched to identify additional relevant trials.

Study selection

Studies were included if they (1) involved patients previously untreated with chemotherapy, locally advanced (stage IIIB) or metastatic (stage IV) NSCLC; (2) were randomized controlled trials (RCTs) with an IBC arm and NIBC arm; (3) were published in full as original articles or as abstracts with sufficient detail, as long as the first author of the study was able to confirm the full results.

Data extraction

All data were extracted independently by two investigators (XQY and CYL) using a standardized form. Extracted data included first author, publication year, patient enrollment period, ethnicity, median age, total number of patients, number of patients eligible for response evaluation, performance status, chemotherapy regimens, hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) and the associated 95 % confidence intervals (CIs), rates of treatment-related deaths and rates of grade 3–4 toxicity effects, such as anemia, neutropenia, thrombocytopenia, nausea/vomiting, diarrhea, and treatment-related death. Disagreements were resolved by discussion with a third author (MFX).

If HR was not directly reported, the log HR and variance were estimated using the method of Tierney et al. [10]. The HRs of OS and PFS were extracted directly from the text, calculated from the reported number of events and the corresponding log-rank p value, or read off the survival curves.

Study quality assessment

We assessed the methodological quality of the studies using the modified Jadad score [11], which evaluates whether the trial responds adequately to the following four questions: (1) whether an appropriate randomization method is reported (0–2 points); (2) whether randomization concealment is reported (0–2 points); (3) whether an appropriate blinding method is reported (0–2 points); and (4) whether withdrawals and dropouts are reported (0–1 points).

Statistical analysis

All meta-analyses were performed using Review Manager 5.2 (Cochrane Collaboration) except publication bias was calculated using STATA SE 12.1 package (StataCorp, College Station, TX); other statistical tests were performed using SPSS for Windows 13.0 (IBM, Chicago, IL). PFS and OS for IBC and NIBC patients were compared using HRs, while dichotomous data for the two treatment groups were compared using risk ratios (RRs). The comparisons were carried out such that RR >1 indicated higher overall response or toxicity in the IBC group, and HR >1 indicated more deaths or progression in the IBC group. RR, OS and PFS were also performed further subgroup analyses between Asian and non-Asian patients. Statistical heterogeneity among trials was assessed using the chi-squared test and expressed using the I2 index [12]. Normally the fixed-effects model was used and weighted according to the Mantel-Haenszel method. When pooled data showed considerable heterogeneity (p < 0.1 or I2 > 50 %), a random-effects meta-analysis model was used. All p values were two-sided, with p < 0.05 defined as the threshold of statistical significance.

Results

Trial flow for meta-analysis

Database searches turned up 1981 potentially eligible publications, of which 312 were excluded as doublet report and 1652 were excluded based on title and abstract review. Of the remaining 17 publications, 6 were excluded because they were RCTs that employed IBC and NIBC as second-line chemotherapy or combined with radiation, four were excluded as single agent in either group or both groups involved irinotecan. In the end, six full papers and one abstract involving 1473 patients with stage IIIB/IV NSCLC were included [1319] (PRISMA flowchart see Fig. 1).
Fig. 1

PRISMA flowchart

Characteristics of included studies

We identified seven RCTs meeting the inclusion criteria: three Phase III RCTs [13, 15, 18], Four Phase II RCTs (Table 1 and Additional file 1) [14, 16, 17, 19]. Four trials involved patient cohorts in Japan [1315, 18], and one trial each was from China [17] and South Korea [16]. Only one trial was from a non-Asian population, namely North Americans [19].
Table 1

Summary of studies

Author

Phase

Race

Jadad score

Group

Regimen

N

Eligible for evaluation

Male (%)

Median age

PS 0-1(%)

Stage IV(%)

Histology Ad. (%)

Median cycles

Negoro S et al.[13] 2003

III

Japanese

5

IP

P: 80mg/m2 day 1, I: 60mg/m2, day 1, 8, 15, q 28days

133

129

76

64

94

62

60

3

PV

P: 80mg/m2 d1, V: 3mg/m2, day 1, 8, 15, q 28days

133

122

80

64

94

63

60

2

Yamamoto N et al.[14] 2004

II

Japanese

5

DI

D: 60mg/m2 day 8, I: 60mg/m2, day 1, 8, q 21days

57

57

67

60

100

75

77

2

DP

P: 80mg/m2 day 1, D: 60mg/m2, day 1, q 21days

51

51

73

62

100

78

71

2

Ohe Y et al.[15] 2007

III

Japanese

5

IP

P: 80mg/m2 day 1, I: 60mg/m2, day 1, 8, 15, q 28days

151

145

67

62

100

79

83

3

TC

T: 200mg/m2 day 1, C: AUC 6, day 1, q 21days

150

145

68

63

100

81

72

3

GP

P: 80mg/m2 day 1, G: 1000mg/m2, day 1, 8, q 21days

151

146

70

61

100

79

74

3

NP

P: 80mg/m2 day 1, N :20mg/m2 , day 1, 8, q 21days

150

145

70

61

100

82

75

3

Han JY et al.[16] 2008

II

Korean

5

IP

P: 30mg/m2, I :65mg/m2, day 1, 8, q21days

75

72

77

58

89

87

71

5

GN

G: 900mg/m2, N :25mg/m2 , day 1, 8, q 21days

71

71

82

60

92

87

69

4

Zhao WY et al.[17] 2012

II

Chinese

4

IP

P: 25mg/m2 day 1–3, I :100mg/m2, day 1, 8, q 21days

31

31

68

59*

68

65

61

3

GP

P: 25mg/m2 day 1–3, G :1000mg/m2, day 1, 8, q 21days

32

32

72

60*

75

59

56

3

Takiguchi Y et al.[18] 2000

III

Japanese

3

IP

P: 80mg/m2 day 1, I: 60mg/m2 , day 1, 8, 15, q 28days

104

98

75

62

94

59

NR

NR

PV

P: 80mg/m2 day 1, V: 3mg/m2 , day 1, 8, 15, q 28days

106

101

Rocha Lima CM et al.[19] 2004

II

American

5

GI

G :1000 mg/ m2 day 1, 8, I: 100 mg/m2, day 1, q 21 days

39

36

72

63

100

77

46

4

GD

G: 1000mg/m2 day 1, 8, D: 40mg/m2, day 1,8, q 21days

39

36

46

57

100

79

59

4

I Irinotecan, P cisplatin, V vindesine, G gemcitabine, N navelbine, D docetaxel, T paclitaxel, C carboplatin, NR not reported, Ad. adenocarcinoma

* This is mean data, not median data.

In total, 590 patients with stage IIIB/IV NSCLC were randomized to receive IBC, and 883 patients to receive NIBC. The IBC regimen was irinotecan and platinum in five trials [13, 1518] and irinotecan and docetaxel [14] or gemcitabine [19] in the remaining trials. None of the patients had been treated prior to trial enrollment, with the exception of six (7.7 %) patients (two in IBC and four in NIBC group) in the study of Rocha Lima et al. [19]; these six patients had recurrent/progressive disease after surgery and/or radiation therapy with no chemotherapy previously.

The trial by Takiguchi et al. [18] did not report the baseline characteristics of the two arms in its abstract, although the authors did report that patients were well-balanced with regard to age, sex, stage, and performance status (PS).

The quality of the seven trials was assessed using the modified Jadad score (Table 1). The full score was seven points. As none of the trials was double-blinded, no trials received the highest possible score.

Overall response rate

All seven trials in the meta-analysis reported overall response rate (ORR). Meta analysis showed that IBC group had the similar ORR compared with NIBC group (RR: 1.08, 95 %CI: 0.94–1.23, p = 0.30; Fig. 2). This meta-analysis was performed using the fixed-effects model since the pooled results showed no significant heterogeneity (χ 2 = 9.94, p = 0.27; I2 = 20 %).
Fig. 2

Comparison of overall response rate between irinotecan-based chemotherapy and non-irinotecan-based chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC

Among the seven trials, one trial reported that IBC was associated with a significantly higher ORR than NIBC (p = 0.041) [16], while another trial reported a tendency towards higher response rate for IBC (p = 0.053) [13], and the remaining trials on Asian cohorts reported similar response rates for the two treatments [14, 15, 17, 18], However, the one trial on a non-Asian population reported a tendency towards lower response rate for IBC (IBC vs NIBC: 12.8 % vs 23.1 %, p = 0.238) [19]. Thus we performed separate meta-analyses for Asian and non-Asian populations. The results showed that the non-Asian population had a tendency towards lower RR value compared to Asian population (RR: 0.56 vs 1.09, p = 0.19).

Overall survival

The meta-analysis from six trials involving Asian patients reported similar OS for IBC and NIBC (HR: 0.94, 95 %CI: 0.85 to 1.04, p = 0.25; Fig. 3) [1318]. However, results for the non-Asian patients showed that IBC had shorter OS than NIBC (HR: 1.87, 95 %CI: 1.15 to 3.04, p = 0.01; Fig. 3) [19]. These two subgroups differed significantly in OS (χ 2 = 7.33, p = 0.007; I2 = 86.4 %). Overall meta-analysis of all seven trials showed similar results (HR: 0.97, 95 %CI 0.88 to 1.07, p = 0.56; Fig. 3).
Fig. 3

Comparison of overall survival between irinotecan-based chemotherapy and non-irinotecan-based chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC

Progression-free survival

Four trials involving 934 patients provided sufficient data to extract HRs for PFS [1416, 19]. The pooled HR from four trials showed similar PFS for IBC and NIBC (HR 1.02, 95 %CI 0.97 to 1.08, p = 0.38; Fig. 4). The two subgroups did not show significant differences in PFS (χ 2 = 0.04, p = 0.85; I2 = 0 %). Another two trials reported that PFS was similar for IBC and NIBC, but they did not report survival curves or log rank p-value, preventing us from including them in the meta-analysis [13, 17].
Fig. 4

Comparison of progression-free survival between irinotecan-based chemotherapy and non-irinotecan-based chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC

Adverse events

Hematological toxicity

Five trials reported data on grade 3–4 hematological toxic effects, such as thrombocytopenia and anemia [1417, 19], while all trials reported data on grade 4 neutropenia. Meta-analysis of pooled data showed that IBC and NIBC were associated with similar incidence of anemia (RR: 1.31, 95 %CI: 0.94 to 1.83, p = 0.11; Fig. 5), neutropenia (RR: 0.74, 95 %CI: 0.53 to 1.04, p = 0.09; Fig. 5) and thrombocytopenia (RR: 0.45, 95 %CI: 0.18 to 1.11, p = 0.08; Fig. 5) for IBC group. The overall effect for hematological toxicity also had no significant difference between IBC and NIBC (RR: 0.79, 95 %CI: 0.60 to 1.04, p = 0.09; Fig. 5). Pooled data for neutropenia and thrombocytopenia showed significant heterogeneity, probably because of the diverse treatment regimes used in the various trials. Therefore we used a random-effects model to perform these meta-analyses.
Fig. 5

Comparison of hematological adverse events between irinotecan-based chemotherapy and non-irinotecan-based chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC

Non-hematological toxicity

All seven trials reported data on grade 3–4 diarrhea. Only one trial did not report data on grade 3–4 nausea/vomiting [18], while another trial did not report data on treatment-related deaths [19]. Meta-analysis showed that IBC was associated with a higher risk of grade 3–4 diarrhea than NIBC (RR: 3.62, 95 %CI: 2.39 to 5.46, p < 0.001), as well as higher risk of nausea/vomiting (RR: 1.65, 95 %CI: 1.08 to2.53, p = 0.02; Fig. 6). In contrast, the two treatments showed similar rates of treatment-related deaths (RR: 1.75, 95 %CI: 0.52 to 5.87, p = 0.36; Fig. 6). The overall effect of non-hematological toxicity for IBC is worse than that of NIBC (RR: 2.25, 95 %CI: 1.60 to 3.17, p < 0.001; Fig. 6). Pooled data for diarrhea and treatment-related deaths showed no significant heterogeneity, but pooled data for nausea/vomiting did. Therefore all these meta-analyses were carried out using a random-effects model.
Fig. 6

Comparison of non-hematological adverse events between irinotecan-based chemotherapy and non-irinotecan-based chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC

Publication bias

We created a funnel plot of the included study data to assess the risk of publication bias. The plot showed no apparent bias (Egger’s test: p = 0.177) (Fig. 7).
Fig. 7

Funnel plot to assess risk of publication bias in included studies

Discussion

The results of this meta-analysis showed that the two types of chemotherapy were associated with similar overall treatment response rate and OS in NSCLC patients with stage IIIB or IV. Also, these two regimens have similar PFS, however, which may not be very convincing as the PFS data of this study is only from three Asian trials and one non-Asian trial. There was no significant difference for hematological toxicity (RR: 0.79, 95 %CI: 0.60 to 1.04, p = 0.09) and significant worse for non-hematological toxicity (RR: 2.28, 95 %CI: 1.60 to3.24, p < 0.001), when IBC compared to NIBC. As chemotherapy is recommended as the 1st-line treatment in the patients with stage IV NSCLC without EGFR mutation, ALK fusion gene arrangement or unknown for these gene mutation statuses in NCCN guideline, we recommend that IBC be considered a 1st-line treatment for NSCLC patients with stage IIIB or IV, especially for the patients without above mutation or gene arrangement. However, the non-hematological toxicity of IBC must be considered. As irinotecan-induced toxicity, including neutropenia and diarrhea, is associated with a single-nucleotide polymorphism (SNP) in the UTG1A1 gene [20] and such that genetic testing for this SNP was approved in 2005 by the US Food and Drug Administration (FDA) as a screening method to identify patients at higher risk of adverse events with IBC, testing for this SNP may help guide proper choice of first-line chemotherapy against NSCLC.

This meta-analysis included 6 Asian trials and only 1 non-Asian trial. The meta-analysis result for OS differed significantly between non-Asians and Asians (HR: 1.87 vs 0.94, p = 0.007), and for ORR had a tendency towards lower RR value when non-Asians compared to Asian population (RR: 0.56 vs 1.09, p = 0.19). However, one non-Asian trial with a small sample study may come to a detrimental result for irinotecan in a non-Asian population, which raise the question of whether our meta-analysis results are applicable to non-Asians and whether different ethnicity had different response to IBC. Large-scale clinical trials of IBC and NIBC to treat SCLC suggest that Asians and non-Asians can respond quite differently to chemotherapy. Whereas a clinical trial in Japanese patients (JCOG 9511) [21] reported better OS with irinotecan combined with platinum than with etoposide combined with platinum (12.8 vs 9.4mo., p = 0.002), a similar trial in North Americans (SWOG 0124) [7] reported similar OS for the two treatments (9.9 vs 9.1mo., p = 0.71). Moreover, efficacy of IBC to treat CRC differed significantly between Caucasians and African-American patients in a North American study (ORR: 41 % vs 28 %; p = 0.008) [22]. These evidences suggested that the ethnic bias may exist in the clinical response to IBC. However, this finding should be confirmed in larger cohorts of Asians and non-Asians with NSCLC, and it should inspire similar meta-analyses in cohorts with CRC or SCLC.

To further examine whether efficacy of IBC depends on patient ethnicity in an even larger cohort, we reviewed the literature for clinical trials of IBC to treat Asian and non-Asian patients with NSCLC, primarily in stage IIIB or IV. The search strategy and data extraction are consistent with the method used in the meta-analysis of this study. The selected criteria were as follows: (1) NSCLC patients with previously untreated with chemotherapy; (2) treated with irinotecan-based doublet regimen; (3) prospective clinical trials Phase II and III. We identified 33 Phase II and III clinical trials published from 1990 to 2014 (see Fig. 8 and Table 2). Even applying less strict inclusion criteria than those we used for the present meta-analysis, we found that 23 of the 33 trials involved Asian patients, while only 10 involved non-Asian patients. This ethnic imbalance was especially true among the 12 trials published after 2007, only one of which involved non-Asian patients. Since OS seemed substantially longer in trials published after 2007 than in trials before that year (14.5 vs 10.7mo. t = −4.518, p = 0.001), perhaps reflecting advances in targeted therapy, we excluded the 12 trials published after 2007. We performed statistical analysis on the remaining 21 trials, including 12 trials that involved 705 Asian patients [13, 14, 18, 2331] and nine trials that involved 384 non-Asian patients, primarily Caucasians [19, 3239]. Statistical Pearson Chi-Square or t-tests showed significantly higher ORR and a tendency toward longer OS in Asian patients than in non-Asian patients (ORR: 37.7 % vs 24.7 %, χ 2 = 18,93, p < 0.001; OS: 11.2 vs 10.1mo., t = 2.036, p = 0.058). PFS, in contrast, was similar between the two populations (median 4.1 vs 4.7mo., t = −0.753, p = 0.467), probably as the data from Asian patients is too small and only five Asian trials reported the PFS data. Although these results did not come exclusively from RCTs or other controlled trials, their consistency with our meta-analysis suggests that IBC is significantly more effective for Asian patients with NSCLC than for non-Asian patients. Therefore, the results of this meta-analysis may not apply to non-Asian populations.
Fig. 8

Trial identification and inclusion in the systematic review of irinotecan-based chemotherapy efficacy in different ethnicities: The literature was selected according to the criteria as follows: (1) NSCLC patients with previously untreated with chemotherapy; (2) treated with irinotecan-based doublet regimen; (3) prospective clinical trials Phase II and III

Table 2

Summary of phase II-III trials of Irinotecan-based doublet regimen on advanced NSCLC as first-line chemotherapy (2006–1990)*

Author

N

Races

Regimen

Efficacy

Toxicity

Median OS (month)

Median PFS (month)

RR (%)

Grade 3/ 4 Neut. (%)

Grade 3/4 Diarrea (%)

Asian trials

Saito H et al.[23] 2006

27

Japanese

Irinotecan 60 mg/m2 day 1, 8, Cisplatin 60 mg/ m2 day 1, q 21 days

12.1

NR

30.0

60.0

22.0

Hino M et a[l24] 2006

39

Japanese

Irinotecan 60 mg/m2 on days 1, 8, 15, Cisplatin 30 mg/ m2 day 1, 8, 15, q 28 days

12.8

2.1

33.3

15.4

15.4

Zhang XR et al.[25] 2006

24

Chinese

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/ m2 day 1, q 28 days

NR

NR

29.2

17.1

5.7

Fukuda M et al.[26] 2004

59

Japanese

Irinotecan 50 mg/m2 on days 1, 8 and 15, Carboplatin AUC 5, q 28 days

10.0

4.0

34.0

60.0

7.0

Yamamoto N et al.[14] 2004

57

Japanese

Irinotecan 60mg/m2 day 1, 8, Docetaxel 60mg/m2 day 8, q 21 days

10.7

4.2

32.0

84.0

16.0

Ichiki M et al.[27] 2003

44

Japanese

Irinotecan 80 mg/m2 day 1, 8, 15, Ifosfamide 1.5 g/m2 day 1 to 3, q 28 days

12.5

5.3

29.5

38.6

6.8

Negoro S et al.[13] 2003

133

Japanese

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

11.7

4.9

43.3

37.0 (grade 4)

12.0

Takeda K et al.[28] 2002

36

Japanese

Irinotecan 50 mg/m2 day 1, 8, 15, Carboplatin AUC 5 day 1, q 28 days

10.2

NR

25.0

76.5

5.9

Ueoka H et al.[30] 2001

44

Japanese

Irinotecan 50 mg/m2 day 1, 8, Cisplatin 60 mg/m2 day 1, 8, q 28days

12.5

NR

48

70.5

25

Nagao K et al.[29] 2000

69

Japanese

Irinotecan 65 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

10.3

NR

47.8

80.3

18.8

Takiguchi Y et al.[18] 2000

104

Japanese

Irinotecan 60mg/m2 day 1, 8, 15, Cisplatin 80mg/m2 day 1, q 28 days

10.5

NR

29.0

50.0 (grade 4)

13.0

Masuda N et al.[31] 1998

69

Japanese

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

10.3

NR

52.0

80

19

Non-Asian trials

Cardenal F et al.[37] 2003

73

Spanish

Irinotecan 200 mg/m2 day 1, Cisplatin 80 mg/m2 day 1, q 21 days

8.2

3.9

24.7

NR

29.0

Jagasia MH et al.[38] 2001

50

Americans

Irinotecan 65 mg/m2 and Cisplatin 30 mg/ m2 day 1, 8, 15, 21, q 42 days

11.6

6.9

36.0

26.0

26.0

DeVore RF et al.[39] 1999

52

Americans

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

9.9

5.1

28.8

46.1

17.3

Pillot GA et al.[32] 2006

42

Americans

Irinotecan 200 mg/m2 day 1 , Carboplatin AUC 5 day 1, q 21days

11.7

6.9

14.0

62.0

5.0

Ziotopoulos P et al.[33] 2005

39

Greeks

Irinotecan 200 mg/m2 day 1, Docetaxel 80 mg/m2 day 1, q 21 days

10.8

3.0

23.0

28.2

23.1

Stathopoulos GP et al.[34] 2005

52

Greeks

Irinotecan 125 mg/m2 day 1, 8, Paclitaxel 135 mg/m2 day 1, q 21 days

NR

6.0

41.0

NR

NR

Murren JR et al.[35] 2005

23

Americans

Irinotecan 50 mg/m2 and Paclitaxel 75 mg/m2 on days 1 and 8 , q 21 days

9.2

2.8

9.0

26.0

5.0

Raez LE et al.[36] 2004

14

Irish

Irinotecan 50mg/m2 day 1, 8, 15, Docetaxel 50mg/m2 day 2, q 28 days

11.0

NR

7.0

21.0

0

Rocha Lima CM et al.[19] 2004

39

Americans

Irinotecan 100 mg/ m2 day 1, Gemcitabine 1000 mg/ m2 day 1, 8, q 21 days

8.0

3.5

12.8

26.0

13.0

NR not reported, Ad. adenocarcinoma, Neut. neutropenia

*The literature was selected according to the criteria as follows: (1) NSCLC patients with previously untreated with chemotherapy; (2) treated with irinotecan-based doublet regimen; (3) prospective clinical trials Phase II and III.

Then what causes efficacy difference in populations? Actually, except that the clinical response to IBC is dependent on the ethnic in NSCLC, the clinical response to other drugs in NSCLC is also different with different population. For example, it has been proved that bevacizumab in combination with chemotherapy can improve clinical outcomes in patients with advanced or recurrent NSCLC. However, compared with global data from SAiL study (ORR 50.7 %, median TTP 7.8mo., median OS 14.6mo.) [40], Asian patients, especially Chinese population, with advanced non-squamous NSCLC seemed to have an advantage over other ethnicities on overall survival after receiving bevacizumab-based first-line treatment (ORR 68.9 %, median TTP 8.8mo., median OS 18.5mo.) [41]. Also, as the rate of EGFR positive mutation is more than 30 % in Asian patients and less than 10 % in Caucasians [4], EGFR-TKI treating NSCLC had higher response in Asian patients than in Caucasians. Then we suspected that different genotype may account for the different clinical response to IBC in different populations. As we know, the SNP of UGT1A1 gene is the hotspot of research at present. Frequencies of these variants depend on ethnicity, with UGT1A1*28 being found more commonly in Caucasians and a higher frequency of UGT1A1*6 being found among Asians [42, 43], both of which were associated with irinotecan-induced severe neutropenia and diarrhea. A study from Korean patients with NSCLC administered irinotecan found that the SNP type of UGT1A1*6 related to the response rate and survival [44]. Thus further study must be investigated into the relationship of SNP of UGT1A1 gene or other genes with the response on NSCLC in different populations.

Our meta-analysis aggregated patients with various histological types of advanced NSCLC, but there is evidence to suggest that irinotecan efficacy may depend on histological type. In one meta-analysis, nedaplatin + irinotecan was more active against squamous cell carcinoma than against non-squamous cell carcinoma, based on overall response rate (51.9 vs 35.1 %, p = 0.115) and OS (14.5 vs 9.1mo., p = 0.127) [45]. Future studies should examine how IBC efficacy varies with histological type of NSCLC, preferably in different ethnicities. We suggest that, regardless of the outcomes of these studies, IBC may be particularly appropriate for treating squamous cell lung carcinoma, given the scarcity of targeted therapies for this carcinoma and a median survival of only 8–10 months, overall response rates of 25 %–35 % with platinum-based therapy [46]. However, clinicians should be aware that the risk of grade 3–4 vomiting and diarrhea is higher with IBC than NIBC, based on our meta-analysis.

Conclusions

In summary, we have found that the efficacy of an irinotecan-based doublet chemotherapy regimen against advanced NSCLC is similar to that of a non-irinotecan-based doublet regimen, at least in Asian patients. Therefore we recommend IBC as first-line chemotherapy in Asian patients, especially for squamous cell lung carcinoma and the patients being not suitable for target therapy. Our results should be interpreted with caution because some trials in our meta-analysis used non-platinum regimens, while the gold standard for treating NSCLC is a platinum-based doublet regimen. Also, the ethnicity for irinotecan seems to be essential and a mixed investigated population may dilute the conclusions. Future meta-analyses should be conducted to compare platinum + irinotecan with platinum + other agents. Also,as EGFR mutant status related to the efficacy of chemotherapy and non-Asian patients have different mutant status with Asian patients, investigation of the activity of irinotecan-based regimens in EGFR mutant patients should also be urged.

Abbreviations

IBC: 

Irinotecan-based chemotherapy

NIBC: 

Non-irinotecan-based chemotherapy

Declarations

Acknowledgments

This study was part supported by a grant from the National Natural Science Foundation of China (No. 81272599) to Dr. Xue-Qin Yang.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Cancer Center, Daping Hospital, Third Military Medical University
(2)
Department of Medical Protection, 537 Hospital of the Chinese People’s Liberation Army

References

  1. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, et al. New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification. Cancer. 1992;70(5):1102–10.PubMedView ArticleGoogle Scholar
  2. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452–62.PubMedView ArticleGoogle Scholar
  3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.PubMedView ArticleGoogle Scholar
  4. Boolell V, Alamgeer M, Watkins DN, Ganju V. The evolution of therapies in Non-small cell lung cancer. Cancers. 2015;7(3):1815–46.PubMed CentralPubMedView ArticleGoogle Scholar
  5. National Comprehensive Cancer Network. Non-small cell lung cancer v.3. 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
  6. Rothenberg ML, Eckardt JR, Kuhn JG, Burris 3rd HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14(4):1128–35.PubMedGoogle Scholar
  7. Lara Jr PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–5.PubMed CentralPubMedView ArticleGoogle Scholar
  8. Lim WT, Lim ST, Wong NS, Koo WH. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians. J Chemother. 2003;15(4):400–5.PubMedGoogle Scholar
  9. Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, et al. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep. 2009;21(4):1005–9.PubMedView ArticleGoogle Scholar
  10. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMed CentralPubMedView ArticleGoogle Scholar
  11. Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-Arbol L, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35(3):609–15.PubMedView ArticleGoogle Scholar
  12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.PubMed CentralPubMedView ArticleGoogle Scholar
  13. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003;88(3):335–41.PubMed CentralPubMedView ArticleGoogle Scholar
  14. Yamamoto N, Fukuoka M, Negoro SI, Nakagawa K, Saito H, Matsui K, et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a west Japan thoracic oncology group study (WJTOG9803). Br J Cancer. 2004;90(1):87–92.PubMed CentralPubMedView ArticleGoogle Scholar
  15. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm cooperative study in Japan. Ann Oncol. 2007;18(2):317–23.PubMedView ArticleGoogle Scholar
  16. Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer. 2008;113(2):388–95.PubMedView ArticleGoogle Scholar
  17. Zhao WY, Chen DY. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese J Oncol. 2012;34(10):775–9.Google Scholar
  18. Takiguchi Y, Nagao K, Nishiwaki Y, Yokoyama A, Saijo N, Ohashi Y, et al. The final results of a randomized phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 2000;29(9 Suppl 1):S 28.View ArticleGoogle Scholar
  19. Rocha Lima CM, Rizvi NA, Zhang C, Herndon 2nd JE, Crawford J, Govindan R, et al. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol. 2004;15(3):410–8.PubMedView ArticleGoogle Scholar
  20. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 1994;54(16):4347–54.PubMedGoogle Scholar
  21. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91.PubMedView ArticleGoogle Scholar
  22. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009;27(25):4109–15.PubMed CentralPubMedView ArticleGoogle Scholar
  23. Saito H, Kudoh S, Nakagawa K, Negoro S, Matsui K, Semba H, et al. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer. Am J Clin Oncol. 2006;29(5):503–7.PubMedView ArticleGoogle Scholar
  24. Hino M, Kobayashi K, Yoshimura A, Takeda Y, Hisakatsu S, Yoneda S, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer. Anticancer Res. 2006;26(6C):4697–703.PubMedGoogle Scholar
  25. Zhang XR, Zhu YZ, Xiu QY, Han FC, Liu DQ, Chu DT. [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese J Oncol]. 2006;28(10):777–9.Google Scholar
  26. Fukuda M, Oka M, Soda H, Kinoshita A, Fukuda M, Nagashima S, et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol. 2004;54(6):573–7.PubMedView ArticleGoogle Scholar
  27. Ichiki M, Rikimaru T, Gohara R, Koga T, Kawayama T, Matunami M, et al. Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer. Oncology. 2003;64(4):306–11.PubMedView ArticleGoogle Scholar
  28. Takeda K, Takifuji N, Uejima H, Yoshimura N, Terakawa K, Negoro S. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer. 2002;38(3):303–8.PubMedView ArticleGoogle Scholar
  29. Nagao K, Fukuoka M, Fujita A, Kurita Y, Saito R, Niitani H, et al. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 lung cancer study group. Gan Kagaku ryoho Cancer Chemotherapy. 2000;27(3):413–21.Google Scholar
  30. Ueoka H, Tanimoto M, Kiura K, Tabata M, Takigawa N, Segawa Y, et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama lung cancer study group. Br J Cancer. 2001;85(1):9–13.PubMed CentralPubMedView ArticleGoogle Scholar
  31. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 lung cancer study group. Br J Cancer. 1998;78(2):251–6.PubMed CentralPubMedView ArticleGoogle Scholar
  32. Pillot GA, Read WL, Hennenfent KL, Marsh S, Gao F, Viswanathan A, et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thoracic Oncol. 2006;1(9):972–8.View ArticleGoogle Scholar
  33. Ziotopoulos P, Androulakis N, Mylonaki E, Chandrinos V, Zachariadis E, Boukovinas I, et al. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Lung Cancer. 2005;50(1):115–22.PubMedView ArticleGoogle Scholar
  34. Stathopoulos GP, Dimitroulis J, Antoniou D, Katis C, Tsavdaridis D, Armenaki O, et al. Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial. Br J Cancer. 2005;93(10):1106–11.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Murren JR, Andersen N, Psyrri D, Brandt D, Nadkarni R, Rose M, et al. Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer. Cancer Biol Therapy. 2005;4(12):1311–5.View ArticleGoogle Scholar
  36. Raez LE, Rosado MF, Santos ES, Reis IM. Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study. Lung Cancer. 2004;45(1):131–2.PubMedView ArticleGoogle Scholar
  37. Cardenal F, Domine M, Massuti B, Carrato A, Felip E, Garrido P, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer. 2003;39(2):201–7.PubMedView ArticleGoogle Scholar
  38. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res. 2001;7(1):68–73.PubMedGoogle Scholar
  39. DeVore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2710–20.PubMedGoogle Scholar
  40. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–40.PubMedView ArticleGoogle Scholar
  41. Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, et al. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Translation Oncol. 2014;16(5):463–8.View ArticleGoogle Scholar
  42. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112(9):1932–40.PubMedView ArticleGoogle Scholar
  43. Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Annals of Oncol. 2011;22(4):890–6.View ArticleGoogle Scholar
  44. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24(15):2237–44.PubMedView ArticleGoogle Scholar
  45. Oshita F, Honda T, Murakami S, Kondo T, Saito H, Noda K, et al. Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials. J Thoracic Oncol. 2011;6(1):128–31.View ArticleGoogle Scholar
  46. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.PubMedView ArticleGoogle Scholar

Copyright

© Yang et al. 2015

Advertisement